Time to Treatment With Nivolumab or Pembrolizumab for Patients With Advanced Melanoma in Everyday Practice.
immunotherapy
melanoma
nivolumab
pembrolizumab
time to treatment
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
accepted:
23
11
2021
entrez:
29
12
2021
pubmed:
30
12
2021
medline:
30
12
2021
Statut:
epublish
Résumé
Background The anti-programmed cell death one antibodies (Anti-PD-1 Ab) pembrolizumab or nivolumab are commonly prescribed to patients with advanced melanoma. The purpose of the current study is to identify baseline clinical characteristics associated with time to treatment initiation (TTI) of pembrolizumab or nivolumab for advanced melanoma and whether treatment delays are associated with differences in survival outcomes. Methods All patients receiving Anti-PD-1 Ab as a first-line treatment for advanced melanoma outside of clinical trials at British Columbia Cancer Agency between 10/2015 and 10/2019 were identified retrospectively. TTI was defined as the interval from pathologic diagnosis of advanced melanoma to first Anti-PD-1 Ab treatment. To determine the association between TTI and baseline characteristics, multivariable Cox proportional hazard regression analyses provided an estimate of the instantaneous relative risk of starting treatment at any time point (hazard ratio [HR] >1 indicates shorter TTI). To describe changes in overall survival (OS) observed for each four-week delay in treatment initiation, multivariable cox proportional hazard regression modelling was also performed. Results In a cohort of 302 patients, the median TTI was 52 days (interquartile range 30.2-99.0). Pulmonary metastases (M1b)/non-central nervous system visceral metastases (M1c) vs. metastases to skin or non-regional lymph nodes (M1a)(HR=1.50, 95% CI=1.12-2.02; p=0.007) and pre-treatment Eastern Cooperative Oncology Group Performance Status (ECOG PS) >1 (vs 0/1, HR=1.50, 95% CI= 1.11-2.01; p=0.008) were associated with earlier TTI. An association between treatment delay and improved OS was observed. Conclusion Patients having visceral metastases and poor baseline ECOG PS were more likely to initiate Anti-PD-1 Ab sooner. The association of shorter TTI with worse OS likely represents confounding by indication (urgent treatment offered to patients with aggressive disease).
Identifiants
pubmed: 34963849
doi: 10.7759/cureus.19835
pmc: PMC8702391
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e19835Informations de copyright
Copyright © 2021, Ksienski et al.
Déclaration de conflit d'intérêts
The authors have declared financial relationships, which are detailed in the next section.
Références
J Clin Oncol. 2020 Nov 20;38(33):3947-3970
pubmed: 32228358
J Clin Oncol. 2008 Feb 1;26(4):527-34
pubmed: 18235113
Control Clin Trials. 1996 Aug;17(4):343-6
pubmed: 8889347
Br J Cancer. 2015 Mar 31;112 Suppl 1:S92-107
pubmed: 25734382
J Clin Oncol. 2019 Jan 1;37(1):52-60
pubmed: 30407895
Eur J Cancer. 2019 Feb;108:61-68
pubmed: 30648631
N Engl J Med. 2017 Oct 5;377(14):1345-1356
pubmed: 28889792
BMJ. 2020 Nov 4;371:m4087
pubmed: 33148535
N Engl J Med. 2018 Aug 23;379(8):722-730
pubmed: 30134131
JAMA Oncol. 2019 Feb 1;5(2):187-194
pubmed: 30422243
JAMA Netw Open. 2021 Mar 1;4(3):e210980
pubmed: 33687443
Cancer. 2020 Jan 1;126(1):76-85
pubmed: 31584709
Cancer Immunol Immunother. 2018 Dec;67(12):1833-1844
pubmed: 30191256
Cancer Immunol Res. 2017 May;5(5):417-424
pubmed: 28411193
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
BMJ. 2002 Jul 27;325(7357):196
pubmed: 12142308
Lancet Oncol. 2017 Jul;18(7):863-873
pubmed: 28592387
Oncologist. 2016 Jul;21(7):848-54
pubmed: 27286787
CA Cancer J Clin. 2017 Nov;67(6):472-492
pubmed: 29028110
J Am Acad Dermatol. 2018 Jan;78(1):40-46.e7
pubmed: 29054718
J Clin Oncol. 2005 Sep 1;23(25):6054-62
pubmed: 16135473
N Engl J Med. 2015 Jun 25;372(26):2521-32
pubmed: 25891173